Residual disease detection and recurrence monitoring*
Guardant RevealTM is the first blood-only test that is able to detect residual and recurrent disease in two weeks, without the need for a tissue biopsy. The test detects circulating tumor DNA (ctDNA) in blood to inform treatment decisions after surgery and detect recurrence as well. Currently, it is developed for early-stage colorectal cancer with testing for additional cancer types to follow.
*Please speak to your physician to find out whether the Guardant Reveal test is appropriate for you.